IP Library Granted Patent US 9,597,413
Granted Patent B2
US 9,597,413 · App. 14/308,554 · Granted Mar 21, 2017

Pulmonary delivery of mRNA

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,597,413
App. No.
14/308,554
Granted
Mar 21, 2017
Kind
B2
Abstract

Disclosed herein are compositions and methods for modulating the production of a protein in a target cell. The compositions and methods disclosed herein are capable of ameliorating diseases associated with protein or enzyme deficiencies.

Claims (9)

1. A method of delivery of messenger RNA (mRNA) for in vivo expression of protein, comprising

administering via inhalation from a nebulizer to a subject a composition comprising an mRNA encoding full-length exogenous CFTR protein such that the administering of the composition results in in vivo expression of the full-length exogenous CFTR protein encoded by the mRNA in lung cells of the subject, wherein the composition further comprises polyethylenimine (PEI).

2. The method of claim 1 , wherein the mRNA comprises a non-naturally occurring nucleotide.

3. The method of claim 1 , wherein the mRNA comprises pseudouridine.

4. A method of delivery of messenger RNA (mRNA) for in vivo expression of protein, comprising

administering via inhalation from a nebulizer to a subject a composition comprising an mRNA encoding full-length exogenous CFTR protein such that the administering of the composition results in in vivo expression of the full-length exogenous CFTR protein encoded by the mRNA in lung cells of the subject,

wherein the mRNA encoding the full-length exogenous CFTR protein is encapsulated in a liposome comprising one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids and one or more PEG-modified lipids.

5. The method of claim 4 , wherein the mRNA comprises a non-naturally occurring nucleotide.

6. The method of claim 4 , wherein the mRNA comprises pseudouridine.

Assignments (3)
CHANGE OF NAME Recorded Jul 20, 2017
From: RANA THERAPEUTICS, INC.
To: TRANSLATE BIO, INC.
Reel/Frame 043267/0165 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 6, 2017
From: SHIRE HUMAN GENETIC THERAPIES, INC.
To: RANA THERAPEUTICS, INC.
Reel/Frame 042177/0032 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2014
From: GUILD, BRAYDON CHARLES; DEROSA, FRANK; HEARTLEIN, MICHAEL
To: SHIRE HUMAN GENETIC THERAPIES, INC.
Reel/Frame 033773/0920 →